SEC Form 4 · accession 0001209191-17-057060
TRANSENTERIX INC. · TRXC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrea Biffi
Director
Period of report
Oct 16, 2017
Accepted (ET)
Oct 17, 2017 · 7:40 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876378
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 16, 2017 | X | 250,000 | $1.00 | A | 590,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A WarrantsF2 | $1.00 | Oct 16, 2017 | X | 250,000 | D | May 3, 2017 | Oct 31, 2017 | Common Stock | 250,000 | 0 | D |
Explanation of responses
- F1On October 16, 2017, the reporting person exercised his Series A warrants to purchase 250,000 shares of common stock of TransEnterix, Inc. (the "Company"), par value $0.001 per share, for a purchase price of $1.00 per share.
- F2The expiration date of the Series A warrant accelerated to the date that is 10 business days after the Company provides written notice to warrant holders of its receipt of FDA clearance for the Senhance System, as set forth in the warrant.